Plain-English translation of NCT04339764 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new surgical treatment for geographic atrophy, an advanced form of dry age-related macular degeneration that causes progressive vision loss. Researchers will take cells from your body, convert them into retinal pigment epithelium (the layer of cells that supports vision), grow them in the lab, and transplant them back into your eye. The goal is to stop or slow further vision loss by replacing the damaged cells.
Geographic atrophy causes the light-sensitive cells in the back of the eye to gradually die, and currently there are very few treatment options available. This trial exists to see if this new cell-based approach can rescue vision and open a path to helping millions of people with this serious condition.
You likely qualify if…
You likely don't qualify if…
If you are accepted into the trial, you will undergo a surgical procedure in which doctors transplant the newly grown retinal cells into the back of your eye. Before surgery, your cells will be collected and grown in the laboratory over several months. After transplantation, you will return for multiple follow-up visits over at least one year to monitor your vision, eye health, and how well the transplanted cells are working.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States